PTEN and triple-negative breast carcinoma: One study used the CRISPR-dCas9-VPR system to target the PTEN proximal promoter via sgRNA to cancer cells with low levels of PTEN expression and found that the dCas9-VPR system increased PTEN expression in melanoma and triple-negative breast cancer cell lines.